Pathology Department, Faculty of Medicine, Cairo University, Egypt.
Pathology Department, Faculty of Medicine, Beni-Suef University, Egypt.
Asian Pac J Cancer Prev. 2022 Jul 1;23(7):2491-2496. doi: 10.31557/APJCP.2022.23.7.2491.
Endometrial cancer (EC) is the most common cancer of the female genital tract. Egypt showed a significant increase in incidence lately of which 25% were premenopausal. Advanced or recurrent disease are mostly unresectable and the traditional adjuvant therapy give modest results with devastating side effects. Late discoveries of immune checkpoint inhibitors have produced promising results. Programmed cell death 1 (PD1) is an immune inhibiting receptor on surface of lymphocytes, which plays critical roles in maintaining immunological self-tolerance. There are two ligands for this receptor, PDL1 and PDL2. PD-L1 is expressed on tumor cells; attaches to PD1, allowing tumor cells to escape from the host immune response. Its prognostic significance in various tumors is controversial and its significance in ECs has just begun to be investigated. Therefore, we investigated the relationship between PDL1 expression and different clinicopathologic parameters in EC cases and its correlation with CD4 and CD8 immune cells, in order to identify the predictive biomarkers for the outcome by immune therapy.
Hundred, paraffin tissue blocks of EC cases were collected and stained with antibodies against PDL1,CD4 and CD8.
PDL1 was positive in 67% of cases in tumor cells and in 61% of cases in immune cells. CD4 and CD8 were expressed in 79% of cases. Statistically significant correlations were observed between PDL1 expression and patients mean age, LVSI, TILS score and CD4+/CD8+ expression.
Those variables can stratify candidates who can benefit most from immunotherapy, or can be chosen for further high cost molecular investigations application.
子宫内膜癌（EC）是女性生殖道最常见的癌症。埃及最近的发病率显著上升，其中 25%为绝经前患者。晚期或复发性疾病大多无法切除，传统的辅助治疗仅能带来适度的效果，且具有破坏性的副作用。免疫检查点抑制剂的最新发现取得了令人鼓舞的结果。程序性细胞死亡 1（PD1）是淋巴细胞表面的一种免疫抑制受体，在维持免疫自身耐受方面发挥着关键作用。该受体有两个配体，PDL1 和 PDL2。PD-L1 在肿瘤细胞上表达；与 PD1 结合，使肿瘤细胞逃避宿主免疫反应。其在各种肿瘤中的预后意义存在争议，其在 EC 中的意义才刚刚开始被研究。因此，我们研究了 PD-L1 表达与 EC 病例不同临床病理参数之间的关系及其与 CD4 和 CD8 免疫细胞的相关性，以便通过免疫治疗确定预测结果的生物标志物。
收集了 100 例 EC 病例的石蜡组织块，并使用针对 PD-L1、CD4 和 CD8 的抗体进行染色。
肿瘤细胞中 67%的病例和免疫细胞中 61%的病例 PD-L1 阳性。CD4 和 CD8 在 79%的病例中表达。PD-L1 表达与患者平均年龄、LVSI、TILS 评分和 CD4+/CD8+表达之间存在显著相关性。
这些变量可以对最能从免疫治疗中获益的候选者进行分层，或选择其进行进一步的高成本分子研究应用。
